Navigation Links
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
Date:1/22/2009

WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML).

Through the partnership, LLS will provide $3.7 million to support Celator's Phase 2B multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy in adult patients less than or equal to 60 years of age with AML in first relapse. Celator expects to start patient enrollment in this study in the first quarter of 2009 in the United States and Canada.

The partnership between Celator and LLS is part of LLS's Therapy Acceleration Program (TAP), which supports private sector and academic-based projects with the goal of advancing investigational therapies with high prospects for providing near-term benefit to patients with blood cancers.

"Celator has discovered a novel way to deliver and enhance the activity of agents that have been the standard of care in AML for decades," said Louis DeGennaro, Ph.D., LLS's chief scientific officer. "There have been many attempts to improve outcomes in this patient population with little success. The data collected on CPX-351 to date, and the enthusiasm of clinical investigators involved in that research, suggest that Celator's approach holds real promise to advance the treatment of AML."

"We are very pleased that The Leukemia & Lymphoma Society sees the potential of CPX-351 and is making this substantial investment," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "LLS has created a well defined, streamlined process for accessing capital for promising new blood cancer treatments. This commitment enhances our ability to further the clinical development of CPX-351
'/>"/>

SOURCE Celator Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. September is Leukemia, Lymphoma and Myeloma Awareness Month
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. Leukemia Drug Proves Safe and Effective Over the Long Term
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
11. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 On September ... sole exhibition focusing on medical design and manufacturing - ... the Shanghai World Expo Exhibition & Convention Center, bringing ... countries and regions to showcase their latest medical-grade raw ... now only one week remaining for free visitor pre-registration ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... HOUSTON , Sept. 16, 2014  DNAtrix, ... that the first patient was treated with the ... plus gamma interferon in a randomized, multicenter, open-label ... "DNAtrix, in collaboration with leading neurosurgeons ... announce the initiation of our randomized Phase Ib ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
... ImpactRx, the pioneer in measuring the impact ... Kjell Nygren, Ph.D. has joined the company as ... company,s position as a state-of-the-art provider of analytical ... the effectiveness of their promotional activities in driving ...
Cached Medicine Technology:New Test to Screen for Glaucoma Damage 2ImpactRx Names Kjell Nygren Vice President, Analytical Services 2
(Date:9/16/2014)... 14, 2014 A new study found that ... stenting of true coronary bifurcation lesions yields similar ... DKCRUSH-VI clinical trial is the first study to ... were reported today at the 26th annual Transcatheter ... Cardiovascular Research Foundation (CRF), TCT is the world,s ...
(Date:9/16/2014)... 16, 2014 Programs and policies that ... of billions of dollars in savings for the US ... Commonwealth Fund. To help spur these types of improvements, ... 10 collaborative groups from across the country to field ... ) - a handbook designed to assist groups working ...
(Date:9/16/2014)... 2014 As part of its Latinos ... Citizens (LULAC) will host the second annual health festival ... feature free health screenings for osteoporosis, HIV, and high ... and cholesterol levels as well as bone marrow typing. ... under 6 years old , The event will also ...
(Date:9/16/2014)... Dennis Thompson HealthDay Reporter ... combination drug therapy aimed at opening the airways and ... older adults with chronic obstructive pulmonary disease (COPD), especially ... COPD patients who received a combination of long-acting beta ... or require hospitalization because of their breathing disorder, compared ...
(Date:9/16/2014)... NC (PRWEB) September 16, 2014 Danny ... on a Fall workshop tour with events throughout the ... the natural running movement and has taught a full ... is now offering ChiWalk-Run and ChiWalking tracks at his ... enjoy the benefits of the Chi techniques. , Workshop ...
Breaking Medicine News(10 mins):Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News:Combo Therapy Best for COPD: Study 2Health News:Combo Therapy Best for COPD: Study 3Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 2Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 3
... 3, 2008 A new study presented ... by researchers for Scientific,Food Solutions,( http://www.scientificfoodsolutions.com/pages/clinicals.html ) ... Vitamin C with,Bioperine(R), provides 275 percent faster ... Reece, President of Scientific Food Solutions said, ...
... the American Association for Dental Research,s (AADR) High School ... with the AADR,s 37th Annual Meeting & Exhibition at ... the High School for Health Professions, the Talented and ... School. The program includes a tour of Baylor College ...
... how to eat during seasons key to maintaining health, ... get bombarded on a,regular basis about health, diets and ... According to the Institute for Integrative Nutrition,the largest nutrition ... to maintaining health and wellness, regardless of which,diet you ...
... Rhytec, Inc. the pioneer,of plasma skin regeneration and ... novel thermal energy called plasma for reversing the ... Food and Drug Administration (FDA),clearance to market a ... already cleared by the FDA for treating facial ...
... Campos Ramirez, 60, was sentenced to 10 years in ... defraud Medicare, Assistant Attorney General,Alice S. Fisher of the ... Southern District of Florida announced today. The scheme,represents the ... of the program., Campos was sentenced today in ...
... Ventas, Inc.,(NYSE: VTR ) ("Ventas" or the ... the Company at the Credit Suisse 2008 Global,Real Estate ... at 2:50 p.m.,Eastern Time., The presentation will be ... http://www.ventasreit.com . Any written materials,accompanying the presentation will ...
Cached Medicine News:Health News:Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand 2Health News:Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating 2Health News:Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating 3Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 2Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 3Health News:Owner of Medicare Billing Service Sentenced to 10 Years In Prison For Role in $170 Million Medicare Fraud Scheme 2
... Blood Pressure Monitoring System extends the ... by providing continuous, real-time derivation of ... parameters are sampled every 5 seconds, ... Central Systolic, Diastolic, and Pulse Pressures ...
... BD Xstar Blade includes a specially designed, ... in prodedure and handling. The Xstar ... process for manufacturing surgical blades. This ... The arch style, single-bevel geometry allows ...
Electric high speed system....
Compressor-cooled plate used to keep blocks cold while sectioning....
Medicine Products: